nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—SLCO1B1—breast cancer	0.307	0.711	CbGaD
Repaglinide—CYP3A4—breast cancer	0.0668	0.155	CbGaD
Repaglinide—ALB—breast cancer	0.0583	0.135	CbGaD
Repaglinide—CYP2C8—Lapatinib—breast cancer	0.0273	0.0856	CbGbCtD
Repaglinide—SLCO1B1—Irinotecan—breast cancer	0.0248	0.0778	CbGbCtD
Repaglinide—CYP3A4—Exemestane—breast cancer	0.0219	0.0687	CbGbCtD
Repaglinide—CYP2C8—Raloxifene—breast cancer	0.0207	0.0649	CbGbCtD
Repaglinide—CYP3A4—Letrozole—breast cancer	0.0186	0.0584	CbGbCtD
Repaglinide—CYP3A4—Anastrozole—breast cancer	0.0166	0.052	CbGbCtD
Repaglinide—CYP3A4—Toremifene—breast cancer	0.0152	0.0476	CbGbCtD
Repaglinide—CYP3A4—Fulvestrant—breast cancer	0.0141	0.0442	CbGbCtD
Repaglinide—CYP2C8—Tamoxifen—breast cancer	0.0137	0.0429	CbGbCtD
Repaglinide—ALB—Irinotecan—breast cancer	0.0136	0.0426	CbGbCtD
Repaglinide—SLCO1B1—Methotrexate—breast cancer	0.0131	0.0412	CbGbCtD
Repaglinide—ALB—Fluorouracil—breast cancer	0.0131	0.0409	CbGbCtD
Repaglinide—CYP3A4—Thiotepa—breast cancer	0.0126	0.0394	CbGbCtD
Repaglinide—CYP3A4—Ixabepilone—breast cancer	0.0115	0.0361	CbGbCtD
Repaglinide—CYP3A4—Lapatinib—breast cancer	0.0111	0.0347	CbGbCtD
Repaglinide—CYP2C8—Paclitaxel—breast cancer	0.0107	0.0334	CbGbCtD
Repaglinide—CYP2C8—Fluorouracil—breast cancer	0.0101	0.0316	CbGbCtD
Repaglinide—CYP3A4—Raloxifene—breast cancer	0.0084	0.0263	CbGbCtD
Repaglinide—ALB—Methotrexate—breast cancer	0.0072	0.0225	CbGbCtD
Repaglinide—CYP3A4—Vinorelbine—breast cancer	0.00615	0.0193	CbGbCtD
Repaglinide—CYP3A4—Tamoxifen—breast cancer	0.00555	0.0174	CbGbCtD
Repaglinide—CYP3A4—Mitoxantrone—breast cancer	0.00541	0.017	CbGbCtD
Repaglinide—CYP3A4—Paclitaxel—breast cancer	0.00432	0.0135	CbGbCtD
Repaglinide—CYP3A4—Irinotecan—breast cancer	0.00426	0.0133	CbGbCtD
Repaglinide—CYP3A4—Vinblastine—breast cancer	0.00379	0.0119	CbGbCtD
Repaglinide—CYP3A4—Docetaxel—breast cancer	0.00312	0.00978	CbGbCtD
Repaglinide—CYP3A4—Doxorubicin—breast cancer	0.00233	0.00729	CbGbCtD
Repaglinide—PPARG—Topotecan—Irinotecan—breast cancer	0.00192	1	CbGdCrCtD
Repaglinide—KCNJ11—mammary gland—breast cancer	0.00174	0.0714	CbGeAlD
Repaglinide—ABCC8—mammary gland—breast cancer	0.0016	0.0658	CbGeAlD
Repaglinide—SLCO1B1—mammary gland—breast cancer	0.00142	0.0582	CbGeAlD
Repaglinide—PPARG—mammary gland—breast cancer	0.00122	0.0502	CbGeAlD
Repaglinide—ALB—mammary gland—breast cancer	0.00115	0.0471	CbGeAlD
Repaglinide—PPARG—nipple—breast cancer	0.00101	0.0415	CbGeAlD
Repaglinide—PPARG—embryo—breast cancer	0.000834	0.0343	CbGeAlD
Repaglinide—CYP2C8—mammary gland—breast cancer	0.000805	0.0331	CbGeAlD
Repaglinide—ABCC8—endometrium—breast cancer	0.000799	0.0329	CbGeAlD
Repaglinide—ABCC8—pituitary gland—breast cancer	0.000723	0.0297	CbGeAlD
Repaglinide—KCNJ11—female reproductive system—breast cancer	0.000719	0.0296	CbGeAlD
Repaglinide—KCNJ11—adrenal gland—breast cancer	0.000701	0.0288	CbGeAlD
Repaglinide—PPARG—epithelium—breast cancer	0.00068	0.028	CbGeAlD
Repaglinide—KCNJ11—female gonad—breast cancer	0.000654	0.0269	CbGeAlD
Repaglinide—PPARG—skin of body—breast cancer	0.000647	0.0266	CbGeAlD
Repaglinide—ABCC8—adrenal gland—breast cancer	0.000646	0.0266	CbGeAlD
Repaglinide—KCNJ11—endocrine gland—breast cancer	0.000608	0.025	CbGeAlD
Repaglinide—SLCO1B1—female reproductive system—breast cancer	0.000586	0.0241	CbGeAlD
Repaglinide—PPARG—uterus—breast cancer	0.000562	0.0231	CbGeAlD
Repaglinide—ABCC8—endocrine gland—breast cancer	0.00056	0.023	CbGeAlD
Repaglinide—PPARG—adipose tissue—breast cancer	0.00055	0.0226	CbGeAlD
Repaglinide—PPARG—female reproductive system—breast cancer	0.000505	0.0208	CbGeAlD
Repaglinide—SLCO1B1—endocrine gland—breast cancer	0.000496	0.0204	CbGeAlD
Repaglinide—PPARG—adrenal gland—breast cancer	0.000493	0.0203	CbGeAlD
Repaglinide—PPARG—bone marrow—breast cancer	0.000477	0.0196	CbGeAlD
Repaglinide—ALB—adrenal gland—breast cancer	0.000463	0.019	CbGeAlD
Repaglinide—PPARG—female gonad—breast cancer	0.00046	0.0189	CbGeAlD
Repaglinide—PPARG—endocrine gland—breast cancer	0.000428	0.0176	CbGeAlD
Repaglinide—KCNJ11—lymph node—breast cancer	0.00042	0.0173	CbGeAlD
Repaglinide—CYP2C8—endometrium—breast cancer	0.000402	0.0165	CbGeAlD
Repaglinide—CYP2C8—pituitary gland—breast cancer	0.000364	0.015	CbGeAlD
Repaglinide—CYP2C8—female reproductive system—breast cancer	0.000333	0.0137	CbGeAlD
Repaglinide—PPARG—lymph node—breast cancer	0.000296	0.0122	CbGeAlD
Repaglinide—CYP2C8—endocrine gland—breast cancer	0.000282	0.0116	CbGeAlD
Repaglinide—ALB—lymph node—breast cancer	0.000277	0.0114	CbGeAlD
Repaglinide—CYP3A4—female reproductive system—breast cancer	0.000226	0.00928	CbGeAlD
Repaglinide—CYP3A4—endocrine gland—breast cancer	0.000191	0.00785	CbGeAlD
Repaglinide—Back pain—Docetaxel—breast cancer	7.65e-05	0.000548	CcSEcCtD
Repaglinide—Pruritus—Thiotepa—breast cancer	7.65e-05	0.000548	CcSEcCtD
Repaglinide—Gastrointestinal pain—Irinotecan—breast cancer	7.64e-05	0.000547	CcSEcCtD
Repaglinide—Gastrointestinal pain—Mitoxantrone—breast cancer	7.64e-05	0.000547	CcSEcCtD
Repaglinide—Oedema—Paclitaxel—breast cancer	7.62e-05	0.000546	CcSEcCtD
Repaglinide—Anaphylactic shock—Paclitaxel—breast cancer	7.62e-05	0.000546	CcSEcCtD
Repaglinide—Nausea—Goserelin—breast cancer	7.51e-05	0.000538	CcSEcCtD
Repaglinide—Pancreatitis—Epirubicin—breast cancer	7.51e-05	0.000538	CcSEcCtD
Repaglinide—Angina pectoris—Epirubicin—breast cancer	7.46e-05	0.000535	CcSEcCtD
Repaglinide—Thrombocytopenia—Paclitaxel—breast cancer	7.46e-05	0.000535	CcSEcCtD
Repaglinide—Urticaria—Mitoxantrone—breast cancer	7.42e-05	0.000532	CcSEcCtD
Repaglinide—Back pain—Capecitabine—breast cancer	7.41e-05	0.000531	CcSEcCtD
Repaglinide—Diarrhoea—Thiotepa—breast cancer	7.4e-05	0.00053	CcSEcCtD
Repaglinide—Skin disorder—Paclitaxel—breast cancer	7.4e-05	0.00053	CcSEcCtD
Repaglinide—Abdominal pain—Mitoxantrone—breast cancer	7.38e-05	0.000529	CcSEcCtD
Repaglinide—Abdominal pain—Irinotecan—breast cancer	7.38e-05	0.000529	CcSEcCtD
Repaglinide—Bronchitis—Epirubicin—breast cancer	7.36e-05	0.000528	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Methotrexate—breast cancer	7.23e-05	0.000518	CcSEcCtD
Repaglinide—Vomiting—Vinorelbine—breast cancer	7.2e-05	0.000516	CcSEcCtD
Repaglinide—Rash—Vinorelbine—breast cancer	7.14e-05	0.000512	CcSEcCtD
Repaglinide—Dermatitis—Vinorelbine—breast cancer	7.13e-05	0.000511	CcSEcCtD
Repaglinide—Urticaria—Fluorouracil—breast cancer	7.1e-05	0.000509	CcSEcCtD
Repaglinide—Headache—Vinorelbine—breast cancer	7.09e-05	0.000509	CcSEcCtD
Repaglinide—Leukopenia—Docetaxel—breast cancer	7.08e-05	0.000508	CcSEcCtD
Repaglinide—Palpitations—Docetaxel—breast cancer	6.99e-05	0.000501	CcSEcCtD
Repaglinide—Pancreatitis—Doxorubicin—breast cancer	6.95e-05	0.000498	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Paclitaxel—breast cancer	6.94e-05	0.000497	CcSEcCtD
Repaglinide—Hyperglycaemia—Epirubicin—breast cancer	6.91e-05	0.000495	CcSEcCtD
Repaglinide—Angina pectoris—Doxorubicin—breast cancer	6.9e-05	0.000495	CcSEcCtD
Repaglinide—Hepatobiliary disease—Methotrexate—breast cancer	6.9e-05	0.000495	CcSEcCtD
Repaglinide—Hypersensitivity—Irinotecan—breast cancer	6.88e-05	0.000493	CcSEcCtD
Repaglinide—Hypersensitivity—Mitoxantrone—breast cancer	6.88e-05	0.000493	CcSEcCtD
Repaglinide—Vomiting—Thiotepa—breast cancer	6.87e-05	0.000493	CcSEcCtD
Repaglinide—Leukopenia—Capecitabine—breast cancer	6.85e-05	0.000491	CcSEcCtD
Repaglinide—Paraesthesia—Paclitaxel—breast cancer	6.84e-05	0.00049	CcSEcCtD
Repaglinide—Hypertension—Docetaxel—breast cancer	6.83e-05	0.00049	CcSEcCtD
Repaglinide—Rash—Thiotepa—breast cancer	6.82e-05	0.000489	CcSEcCtD
Repaglinide—Bronchitis—Doxorubicin—breast cancer	6.81e-05	0.000488	CcSEcCtD
Repaglinide—Dermatitis—Thiotepa—breast cancer	6.81e-05	0.000488	CcSEcCtD
Repaglinide—Headache—Thiotepa—breast cancer	6.77e-05	0.000486	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Epirubicin—breast cancer	6.77e-05	0.000485	CcSEcCtD
Repaglinide—Palpitations—Capecitabine—breast cancer	6.77e-05	0.000485	CcSEcCtD
Repaglinide—Chest pain—Docetaxel—breast cancer	6.73e-05	0.000483	CcSEcCtD
Repaglinide—Arthralgia—Docetaxel—breast cancer	6.73e-05	0.000483	CcSEcCtD
Repaglinide—Nausea—Vinorelbine—breast cancer	6.73e-05	0.000482	CcSEcCtD
Repaglinide—Dyspepsia—Paclitaxel—breast cancer	6.7e-05	0.000481	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	6.69e-05	0.000479	CcSEcCtD
Repaglinide—Jaundice—Epirubicin—breast cancer	6.65e-05	0.000477	CcSEcCtD
Repaglinide—Urinary tract infection—Epirubicin—breast cancer	6.64e-05	0.000476	CcSEcCtD
Repaglinide—Hypertension—Capecitabine—breast cancer	6.61e-05	0.000474	CcSEcCtD
Repaglinide—Hypersensitivity—Fluorouracil—breast cancer	6.59e-05	0.000472	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Paclitaxel—breast cancer	6.57e-05	0.000471	CcSEcCtD
Repaglinide—Hepatitis—Methotrexate—breast cancer	6.55e-05	0.000469	CcSEcCtD
Repaglinide—Chest pain—Capecitabine—breast cancer	6.52e-05	0.000467	CcSEcCtD
Repaglinide—Arthralgia—Capecitabine—breast cancer	6.52e-05	0.000467	CcSEcCtD
Repaglinide—Constipation—Paclitaxel—breast cancer	6.51e-05	0.000467	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	6.47e-05	0.000464	CcSEcCtD
Repaglinide—Hepatobiliary disease—Epirubicin—breast cancer	6.46e-05	0.000463	CcSEcCtD
Repaglinide—Anaphylactic shock—Docetaxel—breast cancer	6.45e-05	0.000463	CcSEcCtD
Repaglinide—Oedema—Docetaxel—breast cancer	6.45e-05	0.000463	CcSEcCtD
Repaglinide—Pruritus—Gemcitabine—breast cancer	6.44e-05	0.000461	CcSEcCtD
Repaglinide—Nausea—Thiotepa—breast cancer	6.42e-05	0.00046	CcSEcCtD
Repaglinide—Sinusitis—Epirubicin—breast cancer	6.4e-05	0.000459	CcSEcCtD
Repaglinide—Hyperglycaemia—Doxorubicin—breast cancer	6.39e-05	0.000458	CcSEcCtD
Repaglinide—Diarrhoea—Irinotecan—breast cancer	6.39e-05	0.000458	CcSEcCtD
Repaglinide—Diarrhoea—Mitoxantrone—breast cancer	6.39e-05	0.000458	CcSEcCtD
Repaglinide—Pruritus—Fluorouracil—breast cancer	6.33e-05	0.000454	CcSEcCtD
Repaglinide—Thrombocytopenia—Docetaxel—breast cancer	6.32e-05	0.000453	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—breast cancer	6.31e-05	0.000452	CcSEcCtD
Repaglinide—Skin disorder—Docetaxel—breast cancer	6.27e-05	0.00045	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Doxorubicin—breast cancer	6.26e-05	0.000449	CcSEcCtD
Repaglinide—Oedema—Capecitabine—breast cancer	6.25e-05	0.000448	CcSEcCtD
Repaglinide—Gastrointestinal pain—Paclitaxel—breast cancer	6.23e-05	0.000446	CcSEcCtD
Repaglinide—Diarrhoea—Gemcitabine—breast cancer	6.22e-05	0.000446	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—breast cancer	6.19e-05	0.000444	CcSEcCtD
Repaglinide—Jaundice—Doxorubicin—breast cancer	6.16e-05	0.000441	CcSEcCtD
Repaglinide—Rhinitis—Epirubicin—breast cancer	6.14e-05	0.00044	CcSEcCtD
Repaglinide—Urinary tract infection—Doxorubicin—breast cancer	6.14e-05	0.00044	CcSEcCtD
Repaglinide—Hepatitis—Epirubicin—breast cancer	6.13e-05	0.000439	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—breast cancer	6.12e-05	0.000439	CcSEcCtD
Repaglinide—Diarrhoea—Fluorouracil—breast cancer	6.12e-05	0.000439	CcSEcCtD
Repaglinide—Thrombocytopenia—Capecitabine—breast cancer	6.12e-05	0.000439	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—breast cancer	6.08e-05	0.000436	CcSEcCtD
Repaglinide—Skin disorder—Capecitabine—breast cancer	6.07e-05	0.000435	CcSEcCtD
Repaglinide—Urticaria—Paclitaxel—breast cancer	6.05e-05	0.000434	CcSEcCtD
Repaglinide—Oedema peripheral—Epirubicin—breast cancer	6.04e-05	0.000433	CcSEcCtD
Repaglinide—Abdominal pain—Paclitaxel—breast cancer	6.02e-05	0.000432	CcSEcCtD
Repaglinide—Hepatobiliary disease—Doxorubicin—breast cancer	5.97e-05	0.000428	CcSEcCtD
Repaglinide—Vomiting—Mitoxantrone—breast cancer	5.94e-05	0.000426	CcSEcCtD
Repaglinide—Vomiting—Irinotecan—breast cancer	5.94e-05	0.000426	CcSEcCtD
Repaglinide—Sinusitis—Doxorubicin—breast cancer	5.93e-05	0.000425	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—breast cancer	5.91e-05	0.000424	CcSEcCtD
Repaglinide—Visual impairment—Epirubicin—breast cancer	5.91e-05	0.000423	CcSEcCtD
Repaglinide—Rash—Irinotecan—breast cancer	5.89e-05	0.000422	CcSEcCtD
Repaglinide—Rash—Mitoxantrone—breast cancer	5.89e-05	0.000422	CcSEcCtD
Repaglinide—Dermatitis—Mitoxantrone—breast cancer	5.88e-05	0.000422	CcSEcCtD
Repaglinide—Dermatitis—Irinotecan—breast cancer	5.88e-05	0.000422	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Docetaxel—breast cancer	5.88e-05	0.000422	CcSEcCtD
Repaglinide—Headache—Irinotecan—breast cancer	5.85e-05	0.000419	CcSEcCtD
Repaglinide—Headache—Mitoxantrone—breast cancer	5.85e-05	0.000419	CcSEcCtD
Repaglinide—Paraesthesia—Docetaxel—breast cancer	5.8e-05	0.000416	CcSEcCtD
Repaglinide—Erythema multiforme—Epirubicin—breast cancer	5.79e-05	0.000415	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—breast cancer	5.79e-05	0.000415	CcSEcCtD
Repaglinide—Vomiting—Gemcitabine—breast cancer	5.78e-05	0.000415	CcSEcCtD
Repaglinide—Rash—Gemcitabine—breast cancer	5.74e-05	0.000411	CcSEcCtD
Repaglinide—Dermatitis—Gemcitabine—breast cancer	5.73e-05	0.000411	CcSEcCtD
Repaglinide—Eye disorder—Epirubicin—breast cancer	5.73e-05	0.000411	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—breast cancer	5.7e-05	0.000409	CcSEcCtD
Repaglinide—Erythema—Methotrexate—breast cancer	5.7e-05	0.000409	CcSEcCtD
Repaglinide—Headache—Gemcitabine—breast cancer	5.7e-05	0.000409	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Capecitabine—breast cancer	5.69e-05	0.000408	CcSEcCtD
Repaglinide—Cardiac disorder—Epirubicin—breast cancer	5.69e-05	0.000408	CcSEcCtD
Repaglinide—Vomiting—Fluorouracil—breast cancer	5.69e-05	0.000408	CcSEcCtD
Repaglinide—Rhinitis—Doxorubicin—breast cancer	5.68e-05	0.000408	CcSEcCtD
Repaglinide—Dyspepsia—Docetaxel—breast cancer	5.68e-05	0.000407	CcSEcCtD
Repaglinide—Hepatitis—Doxorubicin—breast cancer	5.67e-05	0.000407	CcSEcCtD
Repaglinide—Rash—Fluorouracil—breast cancer	5.64e-05	0.000404	CcSEcCtD
Repaglinide—Dermatitis—Fluorouracil—breast cancer	5.63e-05	0.000404	CcSEcCtD
Repaglinide—Paraesthesia—Capecitabine—breast cancer	5.61e-05	0.000402	CcSEcCtD
Repaglinide—Hypersensitivity—Paclitaxel—breast cancer	5.61e-05	0.000402	CcSEcCtD
Repaglinide—Headache—Fluorouracil—breast cancer	5.6e-05	0.000402	CcSEcCtD
Repaglinide—Oedema peripheral—Doxorubicin—breast cancer	5.59e-05	0.0004	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Docetaxel—breast cancer	5.57e-05	0.0004	CcSEcCtD
Repaglinide—Nausea—Mitoxantrone—breast cancer	5.55e-05	0.000398	CcSEcCtD
Repaglinide—Nausea—Irinotecan—breast cancer	5.55e-05	0.000398	CcSEcCtD
Repaglinide—Immune system disorder—Epirubicin—breast cancer	5.54e-05	0.000397	CcSEcCtD
Repaglinide—Constipation—Docetaxel—breast cancer	5.52e-05	0.000396	CcSEcCtD
Repaglinide—Back pain—Methotrexate—breast cancer	5.51e-05	0.000395	CcSEcCtD
Repaglinide—Dyspepsia—Capecitabine—breast cancer	5.5e-05	0.000394	CcSEcCtD
Repaglinide—Arrhythmia—Epirubicin—breast cancer	5.47e-05	0.000392	CcSEcCtD
Repaglinide—Visual impairment—Doxorubicin—breast cancer	5.46e-05	0.000392	CcSEcCtD
Repaglinide—Alopecia—Epirubicin—breast cancer	5.42e-05	0.000388	CcSEcCtD
Repaglinide—Nausea—Gemcitabine—breast cancer	5.4e-05	0.000387	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Capecitabine—breast cancer	5.4e-05	0.000387	CcSEcCtD
Repaglinide—Pruritus—Paclitaxel—breast cancer	5.39e-05	0.000386	CcSEcCtD
Repaglinide—Erythema multiforme—Doxorubicin—breast cancer	5.36e-05	0.000384	CcSEcCtD
Repaglinide—Constipation—Capecitabine—breast cancer	5.34e-05	0.000383	CcSEcCtD
Repaglinide—Erythema—Epirubicin—breast cancer	5.33e-05	0.000382	CcSEcCtD
Repaglinide—Malnutrition—Epirubicin—breast cancer	5.33e-05	0.000382	CcSEcCtD
Repaglinide—Nausea—Fluorouracil—breast cancer	5.31e-05	0.000381	CcSEcCtD
Repaglinide—Eye disorder—Doxorubicin—breast cancer	5.3e-05	0.00038	CcSEcCtD
Repaglinide—Gastrointestinal pain—Docetaxel—breast cancer	5.28e-05	0.000378	CcSEcCtD
Repaglinide—Cardiac disorder—Doxorubicin—breast cancer	5.26e-05	0.000377	CcSEcCtD
Repaglinide—Diarrhoea—Paclitaxel—breast cancer	5.21e-05	0.000374	CcSEcCtD
Repaglinide—Back pain—Epirubicin—breast cancer	5.16e-05	0.00037	CcSEcCtD
Repaglinide—Immune system disorder—Doxorubicin—breast cancer	5.12e-05	0.000367	CcSEcCtD
Repaglinide—Gastrointestinal pain—Capecitabine—breast cancer	5.11e-05	0.000366	CcSEcCtD
Repaglinide—Abdominal pain—Docetaxel—breast cancer	5.1e-05	0.000366	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—breast cancer	5.1e-05	0.000366	CcSEcCtD
Repaglinide—Arrhythmia—Doxorubicin—breast cancer	5.07e-05	0.000363	CcSEcCtD
Repaglinide—Alopecia—Doxorubicin—breast cancer	5.01e-05	0.000359	CcSEcCtD
Repaglinide—Urticaria—Capecitabine—breast cancer	4.96e-05	0.000356	CcSEcCtD
Repaglinide—Abdominal pain—Capecitabine—breast cancer	4.94e-05	0.000354	CcSEcCtD
Repaglinide—Erythema—Doxorubicin—breast cancer	4.94e-05	0.000354	CcSEcCtD
Repaglinide—Malnutrition—Doxorubicin—breast cancer	4.94e-05	0.000354	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—breast cancer	4.85e-05	0.000348	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—breast cancer	4.85e-05	0.000348	CcSEcCtD
Repaglinide—Vomiting—Paclitaxel—breast cancer	4.84e-05	0.000347	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.82e-05	0.000346	CcSEcCtD
Repaglinide—Rash—Paclitaxel—breast cancer	4.8e-05	0.000344	CcSEcCtD
Repaglinide—Dermatitis—Paclitaxel—breast cancer	4.8e-05	0.000344	CcSEcCtD
Repaglinide—Leukopenia—Epirubicin—breast cancer	4.78e-05	0.000342	CcSEcCtD
Repaglinide—Back pain—Doxorubicin—breast cancer	4.77e-05	0.000342	CcSEcCtD
Repaglinide—Headache—Paclitaxel—breast cancer	4.77e-05	0.000342	CcSEcCtD
Repaglinide—Hypersensitivity—Docetaxel—breast cancer	4.76e-05	0.000341	CcSEcCtD
Repaglinide—Palpitations—Epirubicin—breast cancer	4.71e-05	0.000338	CcSEcCtD
Repaglinide—Anaphylactic shock—Methotrexate—breast cancer	4.65e-05	0.000334	CcSEcCtD
Repaglinide—Hypertension—Epirubicin—breast cancer	4.61e-05	0.00033	CcSEcCtD
Repaglinide—Hypersensitivity—Capecitabine—breast cancer	4.6e-05	0.00033	CcSEcCtD
Repaglinide—Pruritus—Docetaxel—breast cancer	4.57e-05	0.000327	CcSEcCtD
Repaglinide—Thrombocytopenia—Methotrexate—breast cancer	4.56e-05	0.000327	CcSEcCtD
Repaglinide—Chest pain—Epirubicin—breast cancer	4.54e-05	0.000326	CcSEcCtD
Repaglinide—Arthralgia—Epirubicin—breast cancer	4.54e-05	0.000326	CcSEcCtD
Repaglinide—Nausea—Paclitaxel—breast cancer	4.52e-05	0.000324	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—breast cancer	4.52e-05	0.000324	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	4.51e-05	0.000323	CcSEcCtD
Repaglinide—Pruritus—Capecitabine—breast cancer	4.42e-05	0.000317	CcSEcCtD
Repaglinide—Leukopenia—Doxorubicin—breast cancer	4.42e-05	0.000317	CcSEcCtD
Repaglinide—Diarrhoea—Docetaxel—breast cancer	4.42e-05	0.000317	CcSEcCtD
Repaglinide—Palpitations—Doxorubicin—breast cancer	4.36e-05	0.000313	CcSEcCtD
Repaglinide—Anaphylactic shock—Epirubicin—breast cancer	4.35e-05	0.000312	CcSEcCtD
Repaglinide—Oedema—Epirubicin—breast cancer	4.35e-05	0.000312	CcSEcCtD
Repaglinide—Diarrhoea—Capecitabine—breast cancer	4.28e-05	0.000307	CcSEcCtD
Repaglinide—Thrombocytopenia—Epirubicin—breast cancer	4.26e-05	0.000306	CcSEcCtD
Repaglinide—Hypertension—Doxorubicin—breast cancer	4.26e-05	0.000306	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—breast cancer	4.24e-05	0.000304	CcSEcCtD
Repaglinide—Skin disorder—Epirubicin—breast cancer	4.23e-05	0.000303	CcSEcCtD
Repaglinide—Chest pain—Doxorubicin—breast cancer	4.2e-05	0.000301	CcSEcCtD
Repaglinide—Arthralgia—Doxorubicin—breast cancer	4.2e-05	0.000301	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—breast cancer	4.18e-05	0.0003	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	4.17e-05	0.000299	CcSEcCtD
Repaglinide—Vomiting—Docetaxel—breast cancer	4.1e-05	0.000294	CcSEcCtD
Repaglinide—Dyspepsia—Methotrexate—breast cancer	4.1e-05	0.000294	CcSEcCtD
Repaglinide—Rash—Docetaxel—breast cancer	4.07e-05	0.000292	CcSEcCtD
Repaglinide—Dermatitis—Docetaxel—breast cancer	4.07e-05	0.000292	CcSEcCtD
Repaglinide—Headache—Docetaxel—breast cancer	4.04e-05	0.00029	CcSEcCtD
Repaglinide—Oedema—Doxorubicin—breast cancer	4.03e-05	0.000289	CcSEcCtD
Repaglinide—Anaphylactic shock—Doxorubicin—breast cancer	4.03e-05	0.000289	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Methotrexate—breast cancer	4.02e-05	0.000288	CcSEcCtD
Repaglinide—Vomiting—Capecitabine—breast cancer	3.97e-05	0.000285	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Epirubicin—breast cancer	3.97e-05	0.000284	CcSEcCtD
Repaglinide—Thrombocytopenia—Doxorubicin—breast cancer	3.94e-05	0.000283	CcSEcCtD
Repaglinide—Rash—Capecitabine—breast cancer	3.94e-05	0.000283	CcSEcCtD
Repaglinide—Dermatitis—Capecitabine—breast cancer	3.94e-05	0.000282	CcSEcCtD
Repaglinide—Headache—Capecitabine—breast cancer	3.92e-05	0.000281	CcSEcCtD
Repaglinide—Skin disorder—Doxorubicin—breast cancer	3.91e-05	0.000281	CcSEcCtD
Repaglinide—Paraesthesia—Epirubicin—breast cancer	3.91e-05	0.00028	CcSEcCtD
Repaglinide—Nausea—Docetaxel—breast cancer	3.83e-05	0.000275	CcSEcCtD
Repaglinide—Dyspepsia—Epirubicin—breast cancer	3.83e-05	0.000275	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—breast cancer	3.8e-05	0.000273	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Epirubicin—breast cancer	3.76e-05	0.000269	CcSEcCtD
Repaglinide—Constipation—Epirubicin—breast cancer	3.72e-05	0.000267	CcSEcCtD
Repaglinide—Nausea—Capecitabine—breast cancer	3.71e-05	0.000266	CcSEcCtD
Repaglinide—Urticaria—Methotrexate—breast cancer	3.7e-05	0.000265	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—breast cancer	3.68e-05	0.000264	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.67e-05	0.000263	CcSEcCtD
Repaglinide—Paraesthesia—Doxorubicin—breast cancer	3.62e-05	0.000259	CcSEcCtD
Repaglinide—Gastrointestinal pain—Epirubicin—breast cancer	3.56e-05	0.000255	CcSEcCtD
Repaglinide—Dyspepsia—Doxorubicin—breast cancer	3.55e-05	0.000254	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Doxorubicin—breast cancer	3.48e-05	0.000249	CcSEcCtD
Repaglinide—Urticaria—Epirubicin—breast cancer	3.46e-05	0.000248	CcSEcCtD
Repaglinide—Constipation—Doxorubicin—breast cancer	3.44e-05	0.000247	CcSEcCtD
Repaglinide—Abdominal pain—Epirubicin—breast cancer	3.44e-05	0.000247	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—breast cancer	3.43e-05	0.000246	CcSEcCtD
Repaglinide—Gastrointestinal pain—Doxorubicin—breast cancer	3.29e-05	0.000236	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—breast cancer	3.29e-05	0.000236	CcSEcCtD
Repaglinide—Hypersensitivity—Epirubicin—breast cancer	3.21e-05	0.00023	CcSEcCtD
Repaglinide—Urticaria—Doxorubicin—breast cancer	3.2e-05	0.000229	CcSEcCtD
Repaglinide—Abdominal pain—Doxorubicin—breast cancer	3.18e-05	0.000228	CcSEcCtD
Repaglinide—Diarrhoea—Methotrexate—breast cancer	3.18e-05	0.000228	CcSEcCtD
Repaglinide—Pruritus—Epirubicin—breast cancer	3.08e-05	0.000221	CcSEcCtD
Repaglinide—Diarrhoea—Epirubicin—breast cancer	2.98e-05	0.000214	CcSEcCtD
Repaglinide—Hypersensitivity—Doxorubicin—breast cancer	2.97e-05	0.000213	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—breast cancer	2.96e-05	0.000212	CcSEcCtD
Repaglinide—Rash—Methotrexate—breast cancer	2.93e-05	0.00021	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—breast cancer	2.93e-05	0.00021	CcSEcCtD
Repaglinide—Headache—Methotrexate—breast cancer	2.91e-05	0.000209	CcSEcCtD
Repaglinide—Pruritus—Doxorubicin—breast cancer	2.85e-05	0.000204	CcSEcCtD
Repaglinide—Vomiting—Epirubicin—breast cancer	2.77e-05	0.000198	CcSEcCtD
Repaglinide—Nausea—Methotrexate—breast cancer	2.76e-05	0.000198	CcSEcCtD
Repaglinide—Diarrhoea—Doxorubicin—breast cancer	2.76e-05	0.000198	CcSEcCtD
Repaglinide—Rash—Epirubicin—breast cancer	2.75e-05	0.000197	CcSEcCtD
Repaglinide—Dermatitis—Epirubicin—breast cancer	2.74e-05	0.000197	CcSEcCtD
Repaglinide—Headache—Epirubicin—breast cancer	2.73e-05	0.000196	CcSEcCtD
Repaglinide—Nausea—Epirubicin—breast cancer	2.59e-05	0.000185	CcSEcCtD
Repaglinide—Vomiting—Doxorubicin—breast cancer	2.56e-05	0.000184	CcSEcCtD
Repaglinide—Rash—Doxorubicin—breast cancer	2.54e-05	0.000182	CcSEcCtD
Repaglinide—Dermatitis—Doxorubicin—breast cancer	2.54e-05	0.000182	CcSEcCtD
Repaglinide—Headache—Doxorubicin—breast cancer	2.52e-05	0.000181	CcSEcCtD
Repaglinide—Nausea—Doxorubicin—breast cancer	2.39e-05	0.000172	CcSEcCtD
Repaglinide—CYP3A4—Metabolism—SLC2A5—breast cancer	6.01e-06	7.26e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NCOR1—breast cancer	5.99e-06	7.23e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GSTM1—breast cancer	5.99e-06	7.23e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PLA2G4A—breast cancer	5.99e-06	7.23e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PTGS2—breast cancer	5.98e-06	7.23e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ALDOA—breast cancer	5.98e-06	7.22e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	5.92e-06	7.15e-05	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—IL6—breast cancer	5.87e-06	7.09e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3CB—breast cancer	5.85e-06	7.07e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOA3—breast cancer	5.84e-06	7.05e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOA3—breast cancer	5.8e-06	7.01e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—APRT—breast cancer	5.8e-06	7.01e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PTGS2—breast cancer	5.8e-06	7.01e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC2A2—breast cancer	5.8e-06	7e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC2A2—breast cancer	5.76e-06	6.96e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	5.74e-06	6.93e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IGF1—breast cancer	5.74e-06	6.93e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GPX1—breast cancer	5.73e-06	6.93e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—AKT2—breast cancer	5.73e-06	6.92e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	5.7e-06	6.89e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—MTR—breast cancer	5.68e-06	6.86e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CPT1A—breast cancer	5.68e-06	6.86e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ABCG2—breast cancer	5.68e-06	6.86e-05	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—PIK3CA—breast cancer	5.68e-06	6.86e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CYP1A1—breast cancer	5.68e-06	6.86e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CPT1A—breast cancer	5.65e-06	6.82e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—MTR—breast cancer	5.65e-06	6.82e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ABCG2—breast cancer	5.65e-06	6.82e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CG—breast cancer	5.65e-06	6.82e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ERCC2—breast cancer	5.63e-06	6.8e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HPGDS—breast cancer	5.57e-06	6.73e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HPGDS—breast cancer	5.54e-06	6.69e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HBA1—breast cancer	5.53e-06	6.68e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CD—breast cancer	5.51e-06	6.65e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HBA1—breast cancer	5.5e-06	6.65e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ANGPTL4—breast cancer	5.46e-06	6.59e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ESRRA—breast cancer	5.46e-06	6.59e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SERPINE1—breast cancer	5.45e-06	6.58e-05	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—AKT1—breast cancer	5.42e-06	6.54e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ACHE—breast cancer	5.4e-06	6.52e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTT1—breast cancer	5.4e-06	6.52e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTT1—breast cancer	5.37e-06	6.49e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ACHE—breast cancer	5.37e-06	6.49e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—MTHFR—breast cancer	5.29e-06	6.39e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PTEN—breast cancer	5.22e-06	6.3e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—NOS3—breast cancer	5.2e-06	6.28e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HADHB—breast cancer	5.17e-06	6.25e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GPI—breast cancer	5.17e-06	6.25e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP17A1—breast cancer	5.11e-06	6.18e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP17A1—breast cancer	5.08e-06	6.14e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTGS1—breast cancer	5.06e-06	6.11e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ENO1—breast cancer	5.06e-06	6.11e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PTEN—breast cancer	5.06e-06	6.11e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	5.04e-06	6.09e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ENO1—breast cancer	5.03e-06	6.08e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTGS1—breast cancer	5.03e-06	6.08e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	5.01e-06	6.06e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—breast cancer	4.98e-06	6.01e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP2D6—breast cancer	4.96e-06	6e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CD—breast cancer	4.96e-06	6e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP2D6—breast cancer	4.94e-06	5.96e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ALDH1A1—breast cancer	4.93e-06	5.96e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ALDH7A1—breast cancer	4.93e-06	5.96e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—RAF1—breast cancer	4.92e-06	5.94e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—ALB—breast cancer	4.9e-06	5.92e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CAV1—breast cancer	4.88e-06	5.9e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOA2—breast cancer	4.87e-06	5.89e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOA2—breast cancer	4.84e-06	5.85e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CB—breast cancer	4.8e-06	5.8e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—FHL2—breast cancer	4.73e-06	5.71e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NME1—breast cancer	4.73e-06	5.71e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ADSL—breast cancer	4.73e-06	5.71e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PHGDH—breast cancer	4.73e-06	5.71e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—UMPS—breast cancer	4.73e-06	5.71e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—FASN—breast cancer	4.73e-06	5.71e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—BCHE—breast cancer	4.71e-06	5.68e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—FASN—breast cancer	4.7e-06	5.68e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NOS3—breast cancer	4.69e-06	5.66e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—BCHE—breast cancer	4.68e-06	5.65e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.66e-06	5.63e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC5A5—breast cancer	4.65e-06	5.61e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HPSE—breast cancer	4.64e-06	5.6e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—LDHB—breast cancer	4.64e-06	5.6e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—BRIP1—breast cancer	4.64e-06	5.6e-05	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—AKT1—breast cancer	4.64e-06	5.6e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC5A5—breast cancer	4.62e-06	5.58e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NQO1—breast cancer	4.49e-06	5.42e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC2A1—breast cancer	4.49e-06	5.42e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC2A1—breast cancer	4.46e-06	5.39e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NQO1—breast cancer	4.46e-06	5.39e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CG—breast cancer	4.45e-06	5.37e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IL2—breast cancer	4.41e-06	5.33e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ABCC1—breast cancer	4.4e-06	5.31e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTA3—breast cancer	4.4e-06	5.31e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HMMR—breast cancer	4.4e-06	5.31e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	4.4e-06	5.31e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP3A4—breast cancer	4.38e-06	5.29e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	4.37e-06	5.28e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	4.36e-06	5.26e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP3A4—breast cancer	4.35e-06	5.26e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	4.33e-06	5.23e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CB—breast cancer	4.33e-06	5.23e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP1B1—breast cancer	4.3e-06	5.2e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PTGS2—breast cancer	4.29e-06	5.18e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP1B1—breast cancer	4.28e-06	5.17e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PPARGC1B—breast cancer	4.26e-06	5.14e-05	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	4.26e-06	5.14e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HSP90AA1—breast cancer	4.22e-06	5.1e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HSP90AA1—breast cancer	4.2e-06	5.07e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—MAPK3—breast cancer	4.11e-06	4.96e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOA1—breast cancer	4.11e-06	4.96e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOA1—breast cancer	4.08e-06	4.93e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP19A1—breast cancer	4.05e-06	4.89e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—STK11—breast cancer	4.05e-06	4.89e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP19A1—breast cancer	4.02e-06	4.86e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—STK11—breast cancer	4.02e-06	4.86e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CA9—breast cancer	4.02e-06	4.86e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTA4—breast cancer	4.02e-06	4.86e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—MYC—breast cancer	4e-06	4.83e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GPX2—breast cancer	3.92e-06	4.73e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTA2—breast cancer	3.92e-06	4.73e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CD—breast cancer	3.91e-06	4.72e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SULT1A1—breast cancer	3.87e-06	4.68e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GPX4—breast cancer	3.87e-06	4.68e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ALB—breast cancer	3.86e-06	4.66e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SRC—breast cancer	3.85e-06	4.65e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.8e-06	4.59e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—IDH1—breast cancer	3.78e-06	4.57e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTA1—breast cancer	3.78e-06	4.57e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.78e-06	4.56e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—COMT—breast cancer	3.76e-06	4.54e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—VEGFA—breast cancer	3.75e-06	4.53e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTP1—breast cancer	3.74e-06	4.52e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—COMT—breast cancer	3.74e-06	4.52e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NAT2—breast cancer	3.74e-06	4.52e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PTEN—breast cancer	3.74e-06	4.52e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTP1—breast cancer	3.72e-06	4.5e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HMOX1—breast cancer	3.69e-06	4.46e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NOS3—breast cancer	3.69e-06	4.46e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ITPR1—breast cancer	3.68e-06	4.45e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PIK3CA—breast cancer	3.68e-06	4.45e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HMOX1—breast cancer	3.67e-06	4.43e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ITPR1—breast cancer	3.66e-06	4.42e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3CA—breast cancer	3.57e-06	4.31e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—MAPK3—breast cancer	3.54e-06	4.28e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ABCB1—breast cancer	3.54e-06	4.28e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ABCB1—breast cancer	3.52e-06	4.26e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—TYMS—breast cancer	3.48e-06	4.2e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—TYMS—breast cancer	3.46e-06	4.18e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTM1—breast cancer	3.44e-06	4.16e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOR1—breast cancer	3.44e-06	4.16e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PLA2G4A—breast cancer	3.44e-06	4.16e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TGFB1—breast cancer	3.44e-06	4.15e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOR1—breast cancer	3.42e-06	4.13e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTM1—breast cancer	3.42e-06	4.13e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PLA2G4A—breast cancer	3.42e-06	4.13e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CB—breast cancer	3.41e-06	4.12e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PTGS2—breast cancer	3.38e-06	4.08e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GPX1—breast cancer	3.29e-06	3.98e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—DPYD—breast cancer	3.28e-06	3.96e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MED12—breast cancer	3.28e-06	3.96e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GPX1—breast cancer	3.28e-06	3.96e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP1A1—breast cancer	3.26e-06	3.94e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP1A1—breast cancer	3.24e-06	3.92e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ERCC2—breast cancer	3.23e-06	3.91e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ALDOA—breast cancer	3.23e-06	3.9e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ERCC2—breast cancer	3.22e-06	3.89e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—KRAS—breast cancer	3.19e-06	3.85e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOA3—breast cancer	3.13e-06	3.78e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC2A2—breast cancer	3.11e-06	3.76e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CPT1A—breast cancer	3.05e-06	3.68e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTR—breast cancer	3.05e-06	3.68e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ABCG2—breast cancer	3.05e-06	3.68e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—MTHFR—breast cancer	3.04e-06	3.67e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—MTHFR—breast cancer	3.02e-06	3.65e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—AKT1—breast cancer	3.01e-06	3.63e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HPGDS—breast cancer	2.99e-06	3.61e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HBA1—breast cancer	2.97e-06	3.59e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PTEN—breast cancer	2.94e-06	3.56e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CA—breast cancer	2.93e-06	3.54e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—AKT1—breast cancer	2.92e-06	3.52e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTT1—breast cancer	2.9e-06	3.5e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ACHE—breast cancer	2.9e-06	3.5e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TP53—breast cancer	2.83e-06	3.42e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CAV1—breast cancer	2.8e-06	3.39e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CAV1—breast cancer	2.79e-06	3.37e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—AKT1—breast cancer	2.77e-06	3.35e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP17A1—breast cancer	2.74e-06	3.32e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ENO1—breast cancer	2.72e-06	3.28e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTGS1—breast cancer	2.72e-06	3.28e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—HRAS—breast cancer	2.71e-06	3.27e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.68e-06	3.24e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.66e-06	3.22e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP2D6—breast cancer	2.66e-06	3.22e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CA—breast cancer	2.64e-06	3.19e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOA2—breast cancer	2.62e-06	3.16e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CG—breast cancer	2.55e-06	3.09e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CG—breast cancer	2.54e-06	3.07e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—FASN—breast cancer	2.54e-06	3.06e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—BCHE—breast cancer	2.53e-06	3.05e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC5A5—breast cancer	2.49e-06	3.01e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC2A1—breast cancer	2.41e-06	2.91e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NQO1—breast cancer	2.41e-06	2.91e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—AKT1—breast cancer	2.39e-06	2.89e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP1B1—breast cancer	2.31e-06	2.79e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.27e-06	2.74e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CD—breast cancer	2.25e-06	2.71e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CD—breast cancer	2.23e-06	2.7e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ALB—breast cancer	2.22e-06	2.68e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOA1—breast cancer	2.2e-06	2.66e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP19A1—breast cancer	2.17e-06	2.62e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—STK11—breast cancer	2.17e-06	2.62e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—AKT1—breast cancer	2.15e-06	2.6e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NOS3—breast cancer	2.12e-06	2.56e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NOS3—breast cancer	2.11e-06	2.55e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CA—breast cancer	2.08e-06	2.51e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—COMT—breast cancer	2.02e-06	2.44e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTP1—breast cancer	2.01e-06	2.43e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HMOX1—breast cancer	1.98e-06	2.39e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ITPR1—breast cancer	1.98e-06	2.39e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CB—breast cancer	1.96e-06	2.36e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CB—breast cancer	1.95e-06	2.35e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTGS2—breast cancer	1.94e-06	2.34e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTGS2—breast cancer	1.93e-06	2.33e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ABCB1—breast cancer	1.9e-06	2.3e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—TYMS—breast cancer	1.87e-06	2.26e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOR1—breast cancer	1.85e-06	2.23e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.85e-06	2.23e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTM1—breast cancer	1.85e-06	2.23e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GPX1—breast cancer	1.77e-06	2.14e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP1A1—breast cancer	1.75e-06	2.11e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ERCC2—breast cancer	1.74e-06	2.1e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—AKT1—breast cancer	1.7e-06	2.05e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTEN—breast cancer	1.69e-06	2.04e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTEN—breast cancer	1.68e-06	2.03e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTHFR—breast cancer	1.63e-06	1.97e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CAV1—breast cancer	1.51e-06	1.82e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CG—breast cancer	1.37e-06	1.66e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CD—breast cancer	1.21e-06	1.46e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CA—breast cancer	1.19e-06	1.44e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ALB—breast cancer	1.19e-06	1.44e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CA—breast cancer	1.19e-06	1.43e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NOS3—breast cancer	1.14e-06	1.38e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CB—breast cancer	1.05e-06	1.27e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTGS2—breast cancer	1.04e-06	1.26e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—AKT1—breast cancer	9.75e-07	1.18e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—AKT1—breast cancer	9.69e-07	1.17e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTEN—breast cancer	9.08e-07	1.1e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CA—breast cancer	6.41e-07	7.74e-06	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—AKT1—breast cancer	5.23e-07	6.32e-06	CbGpPWpGaD
